Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

Biotechnology

Healthcare
$8.44 +3.04%

+$0.26 today

Market cap
$547.12M
Beta
1.80
P/E (TTM)
-1.7
EPS (TTM)
-$5.11
52W Low $5.37High $17.58

Volume 2.36M

Average 1.24M

DNA Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Ginkgo Bioworks Holdings, Inc.NYSE: DNA

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents falls 54.0% from a year ago

Cash & equivalents stood at $143.86M at the end of Q1 FY2026, down 54.0% from a year earlier and down 14.0% from the prior quarter. Over 3 fiscal years it compounded at -49.7% a year.

Context

  • Cash & equivalents amounted to 13.9% of total assets at the end of Q1 FY2026, down 10.2 pp from a year earlier.
  • Cash & equivalents increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -54.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$143.86M-14.0% QoQ
Last fiscal yearDec 2025
$167.2M-70.2% YoY
Year agoMar 2025
$312.42M-54.0% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-54.0%——
1 year-70.2%——
3-year CAGR-49.7%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
167.2M USD
Year-over-year change
-70.2%
4-year CAGR
-42.7%

Cash & Equivalents vs competitors

How DNA compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -54.0% is the 8th highest of 10, against a peer median of -27.5%.
  • Cash & equivalents amounts to 13.9% of total assets for DNA, versus a peer median of 26.9%.
DNA Competitors
Cash & Equivalents for DNA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
VIRVir Biotechnology, Inc.Mar 2026$276.09M USD+0.9%-34.9%26.9%
MBXMBX Biosciences, Inc. Common StockSep 2026$161.69M USD-27.5%+46.0%32.3%
DNAGinkgo Bioworks Holdings, Inc.Mar 2026$143.86M USD-54.0%-49.7%13.9%
REPLReplimune Group, Inc.Dec 2025$122.95M USD-28.6%+1.6%36.9%
VALNValneva SEMar 2026€105.37M EUR-31.1%-27.6%28.3%
ARVNArvinas, Inc.Mar 2026$87.3M USD+7.8%+20.7%13.5%
MGTXMeiraGTx Holdings plcMar 2026$71.54M USD+7.5%-17.1%29.2%
MRVIMaravai LifeSciences Holdings, Inc.Jun 2026$70.09M USD-74.0%-30.0%11.6%
AVBPArriVent BioPharma, Inc. Common StockMar 2026$62.1M USD+24.5%-34.7%17.8%
IOVAIovance Biotherapeutics, Inc.Sep 2026$57.93M USD-63.4%-11.1%5.8%
Peer median (excluding DNA) —-27.5%-17.1%26.9%

Competitors are the stored peer set for DNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents1.55B1.32B944.07M561.57M167.2M
Short-term Investments0000255.42M
Net Receivables149.9M84.03M17.9M22.44M24.03M
Inventory3.36M4.36M46K00
Other Current Assets698K8.71M18.99M18.73M25.19M
Total Current Assets1.72B1.45B1B602.74M471.84M
Property, Plant & Equipment (Net)145.77M718.79M394.99M598.16M528.7M
Goodwill21.31M60.21M49.24M00
Intangible Assets21.64M111.04M82.74M72.51M56.92M
Long-term Investments115.23M111.79M77.91M48.7M15.07M
Tax Assets00000
Other Non-current Assets43.99M87.41M58.71M55.34M47.17M
Total Non-current Assets347.95M1.09B663.59M774.71M647.86M
Total Assets2.07B2.54B1.67B1.38B1.12B
Account Payables8.19M10.45M9.32M14.17M10.57M
Short-term Debt00000
Tax Payables00000
Deferred Revenue33.24M47.82M48.5M30.6M19.98M
Other Current Liabilities40.31M52.51M54.38M26.62M32.12M
Total Current Liabilities134.76M172.96M163.86M107.27M95.97M
Long-term Debt0000417.08M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)155.99M174.77M158.06M98.78M0
Other Non-current Liabilities190.58M42.06M24.43M16.58M98.06M
Total Non-current Liabilities368.85M630.08M404.33M554.13M515.14M
Total Liabilities503.61M803.04M568.19M661.39M611.11M
Common Stock161K190K5K5K6K
Retained Earnings(2.3B)(4.4B)(5.29B)(5.84B)(6.15B)
Accumulated OCI(1.72M)(2.63M)1.48M(1.81M)1.85M
Other Stockholders Equity00000
Minority Interest62.01M0000
Total Equity1.57B1.74B1.1B716.06M508.59M
Total Debt23.03M442.59M239.31M467.73M439.89M
Net Debt(1.53B)(873.2M)(704.76M)(93.84M)272.68M

Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

Intrinsic Alpha fair value

Locked

Current Price

$8.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.